JP7883950B2 - 神経系の状態の処置 - Google Patents
神経系の状態の処置Info
- Publication number
- JP7883950B2 JP7883950B2 JP2022524568A JP2022524568A JP7883950B2 JP 7883950 B2 JP7883950 B2 JP 7883950B2 JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022524568 A JP2022524568 A JP 2022524568A JP 7883950 B2 JP7883950 B2 JP 7883950B2
- Authority
- JP
- Japan
- Prior art keywords
- pnni
- pharmaceutical composition
- treatment
- injury
- spinal cord
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926001P | 2019-10-25 | 2019-10-25 | |
| US62/926,001 | 2019-10-25 | ||
| PCT/EP2020/079979 WO2021078991A1 (en) | 2019-10-25 | 2020-10-25 | Treatment of conditions of the nervous system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022554230A JP2022554230A (ja) | 2022-12-28 |
| JP2022554230A5 JP2022554230A5 (cg-RX-API-DMAC7.html) | 2023-11-06 |
| JP7883950B2 true JP7883950B2 (ja) | 2026-07-02 |
Family
ID=73455660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524568A Active JP7883950B2 (ja) | 2019-10-25 | 2020-10-25 | 神経系の状態の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220380331A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4048257A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7883950B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115023222A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021078991A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4440571A1 (en) * | 2021-11-30 | 2024-10-09 | Evexys Biotech OY | Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514438A (ja) | 1998-05-08 | 2002-05-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | チトクロームp450基質としての7−アルコキシクマリン類 |
| JP2008535824A (ja) | 2005-03-29 | 2008-09-04 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体 |
| JP2016530265A (ja) | 2013-08-12 | 2016-09-29 | ベナロヤ リサーチ インスティテュート アット バージニア メイソン | 免疫調節のための4−メチルウンベリフェロン処置 |
| US20180201640A1 (en) | 2017-01-13 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446154A (zh) * | 2012-05-29 | 2013-12-18 | 中国医学科学院药物研究所 | 香豆素衍生物在防治脑部重大疾病中的应用 |
| US11278518B2 (en) * | 2017-01-13 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatment using 4-methylumbelliferone and derivatives thereof |
-
2020
- 2020-10-25 CN CN202080093141.6A patent/CN115023222A/zh active Pending
- 2020-10-25 EP EP20808020.0A patent/EP4048257A1/en active Pending
- 2020-10-25 JP JP2022524568A patent/JP7883950B2/ja active Active
- 2020-10-25 WO PCT/EP2020/079979 patent/WO2021078991A1/en not_active Ceased
- 2020-10-25 US US17/771,758 patent/US20220380331A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514438A (ja) | 1998-05-08 | 2002-05-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | チトクロームp450基質としての7−アルコキシクマリン類 |
| JP2008535824A (ja) | 2005-03-29 | 2008-09-04 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体 |
| JP2016530265A (ja) | 2013-08-12 | 2016-09-29 | ベナロヤ リサーチ インスティテュート アット バージニア メイソン | 免疫調節のための4−メチルウンベリフェロン処置 |
| US20180201640A1 (en) | 2017-01-13 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
Non-Patent Citations (5)
| Title |
|---|
| Arch. Pharm. Chem. Life Sci.,2017年,350,e1700076, page 1-17 |
| Br. J. Pharmacol.,2019年09月,176(18),pp.3611-3621,DOI:10.1111/bph.14672 |
| Chem. Med. Chem.,2017年,12(16),pp.1349-1358,DOI:10.1002/cmdc.201700282 |
| ChemistrySelect,2016年,1,pp.2742-2749,DOI:10.1002/slct.201600735 |
| European Journal of Medicinal Chemistry,2018年10月,161,pp.292-309,DOI:10.1016/j.ejmech.2018.10.016 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115023222A (zh) | 2022-09-06 |
| JP2022554230A (ja) | 2022-12-28 |
| WO2021078991A1 (en) | 2021-04-29 |
| US20220380331A1 (en) | 2022-12-01 |
| EP4048257A1 (en) | 2022-08-31 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250408 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250722 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251015 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260520 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260622 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7883950 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |